Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Wenjie Liu [1 ]
Yuting Fang [1 ]
Chao Zhang [2 ]
Midan Xiang [1 ]
Lijuan Qi [3 ]
Aijiang Su [2 ]
Yongkun Sun [1 ]
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] Beijing Chaoyang District Sanhuan Cancer Hospital,Department of Medical Oncology
[3] Chinese Academy of Medical Sciences,National Cancer Center, National Clinical Research Center for Cancer/Hebei Cancer Hospital
来源：
BMC Gastroenterology | / 25卷 / 1期
关键词：
Metastatic pancreatic ductal adenocarcinoma; NALIRIFOX; Nab-paclitaxel and gemcitabine; Cost-effectiveness;
D O I：
10.1186/s12876-025-03867-2
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma.
    Abushahin, Laith I.
    Noonan, Anne M.
    Hays, John L.
    Malalur, Pannaga G.
    Manne, Ashish
    Jin, Ning
    Mittra, Arjun
    Elkhatib, Rifat T.
    Roychowdhury, Sameek
    Williams, Terence Marques
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Phase I/II trial of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Waypa, Jordan
    Coats, Jessica
    Blaydorn, Lisa
    McGahey, Kayla
    Sangal, Ashish
    Whitehead, Robert P.
    Khemka, Vivek
    CANCER RESEARCH, 2017, 77
  • [43] HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
    Hingorani, Sunil R.
    Zheng, Lei
    Bullock, Andrea J.
    Seery, Tara E.
    Harris, William P.
    Sigal, Darren S.
    Braiteh, Fadi
    Ritch, Paul S.
    Zalupski, Mark M.
    Bahary, Nathan
    Oberstein, Paul E.
    Wang-Gillam, Andrea
    Wu, Wilson
    Chondros, Dimitrios
    Jiang, Ping
    Khelifa, Sihem
    Pu, Jie
    Aldrich, Carrie
    Hendifar, Andrew E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 359 - +
  • [44] Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel plus Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma
    Baron, Margaret Kelsey
    Wang, Xuechen
    Nevala-Plagemann, Christopher
    Moser, Justin C.
    Haaland, Benjamin
    Garrido-Laguna, Ignacio
    PANCREAS, 2021, 50 (06) : 796 - 802
  • [45] Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
    Shui, Lin
    Cheng, Ke
    Li, Xiaofen
    Shui, Pixian
    Li, Shuangshuang
    Peng, Yang
    Li, Jian
    Guo, Fengzhu
    Yi, Cheng
    Cao, Dan
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [46] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [47] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
    Ingram, Myles A.
    Lauren, Brianna N.
    Pumpalova, Yoanna
    Park, Jiheum
    Lim, Francesca
    Bates, Susan E.
    Kastrinos, Fay
    Manji, Gulam A.
    Kong, Chung Yin
    Hur, Chin
    CANCER REPORTS, 2022, 5 (09)
  • [48] A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    Borazanci, Erkut Hasan
    Bahary, Nathan
    Oberstein, Paul Eliezer
    Chung, Vincent
    Skeel, Roland T.
    Chiorean, E. Gabriela
    Greenstein, Andrew E.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Mann, Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
    Azmi, Asfar S.
    Khan, Husain Yar
    Muqbil, Irfana
    Aboukameel, Amro
    Neggers, Jasper E.
    Daelemans, Dirk
    Mahipal, Amit
    Dyson, Gregory
    Kamgar, Mandana
    Al-Hallak, Mohammad Najeeb
    Tesfaye, Anteneh
    Kim, Steve
    Shidham, Vinod
    Mohammad, Ramzi M.
    Philip, Philip A.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1338 - 1348
  • [50] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747
12345